Indaptus Therapeutics to initiate dosing of patients at higher Decoy20 dose

Indaptus Therapeutics provides an update regarding key clinical advancements.The independent Safety Review Committee overseeing the Company’s Phase 1 clinical trial convened in August to review the safety data at the higher Decoy20 dose with single dose administration and the safety data at the lower Decoy20 dose with weekly administration. The encouraging data has led to the decision to: Continue dosing additional patients at the lower Decoy20 dose on a weekly schedule; Initiate dosing patients at the higher Decoy20 dose on a weekly schedule